Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Thailand

King Chulalongkorn Memorial Hospital, Bangkok, Pathumwan